Stockscreener 앱 받기
0.00%
전일 마감가:
$4.70
열려 있는:
$4.41
하루 거래량:
3,330
Relative Volume:
33.00
시가총액:
$N/A
수익:
$3.07M
순이익/손실:
$-26.16M
주가수익비율:
-0.722
EPS:
-6.51
순현금흐름:
$-17.84M
1주 성능:
+13.92%
1개월 성능:
-36.27%
6개월 성능:
-57.97%
1년 성능:
+14.04%
1일 변동 폭
$4.41
$4.86
1주일 범위
$4.41
$4.86
52주 변동 폭
$4.41
$4.86
옵젠 Stock (OPGN) Company Profile
OPGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OPGN
Opgen Inc
|
4.70 | 0 | 3.07M | -26.16M | -17.84M | -6.51 |
|
ABT
Abbott Laboratories
|
132.02 | 231.49B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
104.51 | 154.81B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
380.39 | 145.13B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
81.24 | 108.21B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.66 | 44.64B | 5.54B | 4.18B | 623.10M | 7.00 |
옵젠 Stock (OPGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2019-03-01 | 개시 | Alliance Global Partners | Buy |
| 2018-02-07 | 재확인 | H.C. Wainwright | Buy |
| 2016-06-29 | 개시 | Rodman & Renshaw | Buy |
옵젠 주식(OPGN)의 최신 뉴스
OpGen (NASDAQ:OPGN) Coverage Initiated at StockNews.com - Defense World
Fortrea (NASDAQ:FTRE) and OpGen (NASDAQ:OPGN) Head-To-Head Review - Defense World
OpGen Delays 10-Q Filing Amid Operational Challenges - TipRanks
OpGen (NASDAQ:OPGN) Earns Sell Rating from Analysts at StockNews.com - Defense World
OpGen, Inc. to Host Earnings Call - ACCESS Newswire
OpGen Subsidiary Curetis and Leader Life Sciences Enter into Unyvero Distribution Partnership for U.A.E. and Qatar - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN) - Defense World
StockNews.com Initiates Coverage on OpGen (NASDAQ:OPGN) - Defense World
OpGen (NASDAQ:OPGN) Coverage Initiated by Analysts at StockNews.com - Defense World
OpGen (NASDAQ:OPGN) Shares Pass Above 50-Day Moving Average – Time to Sell? - Defense World
OpGen (NASDAQ:OPGN) Now Covered by StockNews.com - Defense World
OpGen Delays Yearly Report Amid Operational Challenges - TipRanks
Antimicrobial Susceptibility Testing Market Expecting Huge Demand in Upcoming Years Accelerate Diagnostics - openPR.com
Antimicrobial Resistance Surveillance Global Market Report 2025: Steady Growth, And Increased Awareness Propel - EIN News
OpGen (NASDAQ:OPGN) Now Covered by Analysts at StockNews.com - Defense World
Blood Culture Tests Market Size is Projected to Reach USD - GlobeNewswire
Blood Culture Screening Devices Market Rewriting its Growth Cycle | bioMérieux SA, OpGen, T2 Biosystems - Newstrail
Antimicrobial Resistance Surveillance Market is expected to generate a revenue of USD 9.86 Billion by 2032, Globally, at 5.65% CAGR: Verified Market Research - The Malaysian Reserve
Antimicrobial Resistance Surveillance Market is expected to generate a revenue of USD 9.86 Billion by 2032, Globally, at 5.65% CAGR: Verified Market Research® - PR Newswire UK
Blood Stream Infection Testing Global Market Report 2025: Trends, Forecasts, and Competitor Analysis - EIN News
Blood Culture Test Market to Reach $8.18 Billion | CAGR of 9.3% - openPR
Global Antimicrobial Resistance Surveillance Market to Reach USD 9.50 Billion by 2032, Growing at a CAGR of 5.47% - WICZ
Antimicrobial Resistance Diagnostic Markets, Strategies and Trends Report 2024 with Executive Guides and 5 Year Forecasts - GlobeNewswire Inc.
OpGen Faces Delisting from Nasdaq Following Appeal Decision - Defense World
OpGen faces Nasdaq delisting, to trade OTC By Investing.com - Investing.com Australia
OpGen faces Nasdaq delisting, to trade OTC - Investing.com India
OpGen’s subsidiary Ares Genetics provides update on collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR) - Marketscreener.com
Electronic evaluation of infection risk from room environment and - ResearchGate
OpGen Inc sees significant stock purchase by AEI Capital Ltd - Investing.com South Africa
OpGen Inc shareholder AEI Capital Ltd increases stake with $1.9 trillion purchase - Investing.com Nigeria
OpGen Inc adds new COO and Company Secretary By Investing.com - Investing.com Nigeria
옵젠 (OPGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.95%
0.20%
자본화:
|
볼륨(24시간):